Spots Global Cancer Trial Database for breast lobular carcinoma in situ
Every month we try and update this database with for breast lobular carcinoma in situ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | NCT06195306 | Breast Atypical... Breast Carcinom... Breast Ductal C... Breast Lobular ... | Biospecimen Col... Mammography Omega-3-Acid Et... Questionnaire A... Random Periareo... Tamoxifen | 45 Years - 65 Years | National Cancer Institute (NCI) | |
| EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer | NCT05086705 | Breast Carcinom... Breast Ductal C... Breast Lobular ... Hot Flashes | EMBr Wave Questionnaire A... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer | NCT03323658 | Breast Atypical... Breast Atypical... Breast Ductal C... Breast Lobular ... Invasive Breast... | Bexarotene Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ | NCT04570956 | Breast Atypical... Breast Lobular ... Breast Atypical... | Tamoxifen Topical 4-OHT( ... Placebo | 18 Years - 80 Years | Mayo Clinic | |
| Impact of Dietary Inflammatory Potential on Breast Cancer Risk | NCT05178498 | Breast Atypical... Breast Atypical... Breast Carcinom... Breast Lobular ... Breast Sclerosi... | Follow-Up Physical Examin... Questionnaire A... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery | NCT03317405 | Breast Ductal C... Breast Lobular ... Stage 0 Breast ... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Endoxifen Hydro... Placebo Adminis... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer | NCT05941520 | Breast Atypical... Breast Carcinom... Breast Ductal C... Breast Lobular ... | Acolbifene Hydr... Biospecimen Col... Mammography Random Periareo... Tamoxifen | 35 Years - | National Cancer Institute (NCI) | |
| Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer | NCT03323658 | Breast Atypical... Breast Atypical... Breast Ductal C... Breast Lobular ... Invasive Breast... | Bexarotene Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | NCT06195306 | Breast Atypical... Breast Carcinom... Breast Ductal C... Breast Lobular ... | Biospecimen Col... Mammography Omega-3-Acid Et... Questionnaire A... Random Periareo... Tamoxifen | 45 Years - 65 Years | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
